Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Haematology"
DOI: 10.1111/ejh.13492
Abstract: Venetoclax combined with hypomethylating agents is a new therapeutic strategy frequently used for treating AML patients who are not eligible for conventional chemotherapy. However, high response rates are heterogeneous due to different mechanisms mediating resistance… read more here.
Keywords: inhibition venetoclax; improves therapeutic; venetoclax; mcl inhibition ... See more keywords